July 16, 2009 (FinancialWire) — Oxygen Biotherapeutics, Inc. (OTCBB: OXBO) (Current Market Cap: US$ 88.82 Mil.) has closed on a $5 million financing tranche with the Vatea Fund, Segregated Portfolio under a June 8 securities purchase agreement.

Costa Mesa, California-based Oxygen Biotherapeutics commercializes pharmaceuticals and medical devices in the field of oxygen therapeutics and defense medicine.

The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.